Clinical Trials Logo
  1. Home
  2. Pancreatic Cancer
  3. NCT05187312
  4. Details
NCT05187312 Clinical Trial

Registry for Advanced Endoscopy

Pancreatic Cancer Clinical Trial

— ERDB  

Official title:
Research Registry for Endoscopic Treatment and Diagnostics

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05187312
Other study ID # 2021-7616
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 14, 2022
Est. completion date January 14, 2032

Study information
Verified date April 2024
Source Region Stockholm
Contact Erik von Seth, MD, PhD
Phone +46812380000
Email erik.von.seth@ki.se
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Observational registry including endoscopic diagnostic and therapeutic interventions in the gastrointestinal tract

Recruitment information / eligibility
Status Recruiting
Enrollment 1000
Est. completion date January 14, 2032
Est. primary completion date January 14, 2032
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Clinical indication for endoscopic intervention/procedure Exclusion Criteria: - No informed consent - Age <18 years

Study Design

Related Conditions & MeSH terms

Intervention

Procedure:
• Endoscopic retrograde Cholangio- pancreatography
Endoscopic intervention in the biliary or pancreatic duct
• Endoscopic ultrasound
Endoscopic investigation/intervention with ultrasound

Locations
Country Name City State
Sweden Karolinska University Hospital Stockholm

Sponsors (2)
Lead Sponsor Collaborator
Region Stockholm Karolinska Institutet

Country where clinical trial is conducted

Sweden, 

Outcome
Type Measure Description Time frame Safety issue
Primary Adverse events Incidence of Adverse events following endoscopic procedures. Measured as percentage of individuals with an adverse event 30-days and 60-days post-procedure
Primary Diagnostic yield Diagnostic yield after tissue sampling 1-year follow up
See also
  Status Clinical Trial Phase
Completed NCT05305001 - Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Recruiting NCT06054984 - TCR-T Cells in the Treatment of Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Terminated NCT03140670 - Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy Phase 2
Terminated NCT00529113 - Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer Phase 1
Recruiting NCT05168527 - The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05391126 - GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care N/A
Terminated NCT03300921 - A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer Phase 1
Completed NCT03153410 - Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas Early Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Recruiting NCT05679583 - Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer Phase 2
Recruiting NCT04183478 - The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer Phase 2/Phase 3
Terminated NCT03600623 - Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Recruiting NCT05351983 - Patient-derived Organoids Drug Screen in Pancreatic Cancer N/A
Completed NCT04290364 - Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study